ClinicalTrials.gg
CompletedNCT01650194Updated Dec 10, 2024Results posted

A Study to Determine Safety and Tolerability of Enzalutamide (MDV3100) in Combination With Abiraterone Acetate in Bone Metastatic Castration-Resistant Prostate Cancer Patients

A Phase 2 interventional study of enzalutamide and abiraterone acetate in Metastatic Castration-Resistant Prostate Cancer, sponsored by Astellas Pharma Global Development, Inc.. Completed at 1 site in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2024-12-10.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Sex
Male
01

Study summary

The purpose of this study was to explore the safety and tolerability of enzalutamide in combination with abiraterone acetate plus prednisone. Subjects diagnosed with cancer of the prostate that was getting worse and spreading to the bone despite receiving hormone treatment were enrolled and received study treatment until disease progression.

Read the detailed description

For the study duration, all subjects maintained androgen deprivation with a gonadotropin releasing hormone (GnRH) agonist or antagonist or orchiectomy. Study drug was administered until disease progression. Disease progression was defined as a composite endpoint consisting of either clinical deterioration, radiographic progression or prostate-specific antigen (PSA) progression according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria.

02

Conditions studied

  • Metastatic Castration-Resistant Prostate Cancer

Browse trials for

Keywords

  • abiraterone acetate
  • prednisone
  • enzalutamide
  • cancer
  • prostate
  • MDV3100
03

In context

Neoplasms

10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's enrollment of 60 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features
  • Presence of disease to the bone
  • Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH) analogue or orchiectomy (i.e., surgical or medical castration)
  • Subject receiving bisphosphonate or denosumab therapy must have been on stable doses for at least 4 weeks prior to Day 1
  • Progressive disease defined as one or more of the following three criteria (Note: subjects who received an antiandrogen must demonstrate disease progression following discontinuation of antiandrogen):

    • PSA progression defined by a minimum of two rising PSA levels with an interval of ≥ 1 week between each determination. The PSA value at the Screening visit should be ≥ 2 ng/mL
    • Soft tissue disease progression as defined by the (RECIST 1.1)
    • Bone disease progression defined by PCWG2 criteria (two or more new lesions on bone scan compared with prior scan)
  • Subject previously treated with chemotherapy must have no more than two prior chemotherapy regimens for the treatment of metastatic prostate cancer
  • (ECOG) performance status of 0-2
  • Agree to use a double-barrier method of which involves the use of a condom in combination with one of the following: contraceptive sponge, diaphragm, or cervical ring with spermicidal gel or foam, if having sex with a woman of during the length of the study and for one week after abiraterone is discontinued and for at least three months after enzalutamide is discontinued
  • Subject agrees not to participate in another interventional study while on treatment

Exclusion criteria

Exclusion Criteria:

  • Known or suspected in the brain
  • \< 1,000/μL, count \< 75,000/μL, and \< 9 g/dL (NOTE: subject may not have received any growth factors or blood transfusions within seven days of the hematologic laboratory values obtained at the Screening visit)
  • Total (TBL), (ALT) or aspartate aminotransferase (AST) > 2.5 times the
  • Creatinine (Cr) > 2 mg/dL
  • Treatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide), 5-α reductase inhibitors (finasteride, dutasteride), estrogens, chemotherapy, or biologic therapy within 4 weeks of Day 1 visit
  • Radiation therapy within 3 weeks (if single fraction of radiotherapy within 2 weeks) of Day 1 visit, or radionuclide therapy within 8 weeks of Day 1
  • Planned palliative procedures for alleviation of bone pain such as radiation therapy or surgery
  • Structurally unstable bone lesions suggesting impending fracture
  • History of seizure or any condition that may predispose to seizure including, but not limited to underlying brain injury, stroke, primary brain tumors, , or alcoholism. Also, history of loss of consciousness or within 12 months of enrollment (Day 1 visit)
  • cardiovascular disease including:

    • Myocardial infarction within 6 months of Screening visit;
    • Uncontrolled angina within 3 months of Screening visit;
    • Congestive heart failure (NYHA) class 3 or 4, or subjects with history of congestive heart failure NYHA class 3 or 4 in the past, or history of anthracycline or anthracenedione (mitoxantrone) treatment, unless a screening echocardiogram or multi-gated acquisition scan () performed within three months of the Screening visit results in a left ventricular ejection fraction that is ≥ 45%
    • History of clinically significant ventricular arrhythmias (e.g., ventricular tachycardia, ventricular fibrillation, torsade de pointes)
    • Prolonged interval by the Fridericia correction formula (QTcF) on the (ECG) > 470 msec.
    • History of Mobitz II second degree or third degree heart block without a permanent pacemaker in place
    • Hypotension (systolic blood pressure \< 86 mmHg or bradycardia with a heart rate of \<50 beats per minute on the ECG., unless pharmaceutically induced and thus reversible (i.e. beta blockers).
    • Uncontrolled hypertension as indicated by a resting systolic blood pressure >170 mmHg or diastolic blood pressure >105 mmHg
  • Prior use of ketoconazole, abiraterone acetate or enzalutamide, or participation in a previous clinical trial of ketoconazole, abiraterone acetate or enzalutamide
  • History of significant bleeding disorder unrelated to cancer, including:

    • Diagnosed congenital bleeding disorders (e.g., von Willebrand's disease)
    • Diagnosed acquired bleeding disorder within one year (e.g., acquired anti-factor VIII antibodies) of Screening visit
    • History of GI bleeding within 6 months of Screening visit
  • Active or symptomatic viral hepatitis or chronic liver disease
  • Known history of pituitary or adrenal dysfunction
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Enzalutamide + Abiraterone + Prednisone

    Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.

    Drug: enzalutamide · Drug: abiraterone acetate · Drug: prednisone

Interventions

  • Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).

    Also known as: MDV3100

  • Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).

  • Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    A treatment-emergent adverse event (TEAE) was defined as an adverse event occurring or worsening between the start of study treatment date and the latest date of 30 days after the last dose date or the 30-day follow-up visit date, and not later than the data cut-off date or the date of death. AEs, including abnormal clinical laboratory values, were graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) guidelines (V4.03).

    Time frame: From the first dose of study drug administration up 30 days following the last dose of study drug date, with a median duration of treatment of 10.1 months.

Secondary outcomes

  1. Change From Baseline in Testosterone Concentration in Bone Marrow Aspirate

    Testosterone concentration in bone marrow aspirate was measured by laboratory results derived from bone marrow samples processed through liquid chromatography mass spectrometry.

    Time frame: Baseline and Week 9

  2. Change From Baseline in Dihydrotestosterone (DHT) Concentration in Bone Marrow Aspirate

    DHT concentration in bone marrow aspirate was to be measured by laboratory results derived from bone marrow samples processed through liquid chromatography mass spectrometry. DHT bone data were not collected.

    Time frame: Baseline and Week 9

  3. Change From Baseline in Cortisol in Bone Marrow Aspirate

    Cortisol in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.

    Time frame: Baseline and Week 9

  4. Change From Baseline in Androstenedione in Bone Marrow Aspirate

    Androstenedione in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.

    Time frame: Baseline and Week 9

  5. Change From Baseline in Progesterone in Bone Marrow Aspirate

    Progesterone in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.

    Time frame: Baseline and Week 9

  6. Change From Baseline in Pregnenolone in Bone Marrow Aspirate

    Pregnenolone in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.

    Time frame: Baseline and Week 9

  7. Change From Baseline in Testosterone Concentration in Blood

    Testosterone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

    Time frame: Baseline and Week 9

  8. Change From Baseline in DHT Concentration in Blood

    DHT concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry. The endpoint could not be analyzed since no participants had DHT levels over the lower limit of quantification (LLOQ).

    Time frame: Baseline and Week 9

  9. Change From Baseline in Cortisol Concentration in Blood

    Cortisol concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

    Time frame: Baseline and Week 9

  10. Change From Baseline in Androstenedione Concentration in Blood

    Androstenedione concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

    Time frame: Baseline and Week 9

  11. Change From Baseline in Progesterone Concentration in Blood

    Progesterone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

    Time frame: Baseline and Week 9

  12. Change From Baseline in Pregnenolone Concentration in Blood

    Pregnenolone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

    Time frame: Baseline and Week 9

  13. Change From Baseline to End-of-Treatment (EoT) in Prostate-Specific Antigen (PSA) Levels

    Prostate-specific antigen progression by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) was defined as a PSA increase ≥25% and ≥2 ng/ml above the post-baseline nadir, and which was confirmed by the first subsequent value of 3 or more weeks later.

    Time frame: Baseline and EoT; the median duration of treatment was 10.1 months.

  14. Progression Free Survival (PFS)

    PFS was measured as the time from the date of first dose of any drug of the study combination treatment until the first evidence of documented progression (a composite endpoint consisting of radiographic progression or PSA progression by PCWG2 or clinical deterioration) or death in the absence of progression (whichever came first) or the date last known to be progression free. The Kaplan-Meier (KM) 95% CI was based on Brookmeyer and Crowley robust non-parametric method.

    Time frame: Up to 1849 days

  15. Percentage of Participants With Objective Response for Soft Tissue Lesions According to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)

    Objective response was based on RECIST version 1.1 for soft tissue lesion on Magnetic resonance imaging (MRI) / Computerized tomography (CT) and the PCWG2 guidelines for bone lesions on bone scans and was defined as partial response (PR) or complete response (CR) based on the investigators' assessments of target, non-target and new lesions while on study treatment. The 95% for objective response rate was based on exact binomial 95% confidence interval (Clopper-Pearson).

    Time frame: Up to 1849 days

  16. Bone Scan Response at EoT

    PD: ≥1 of 3 criteria: PSA progression: ≥2 rising PSA levels, interval of ≥1 week between each determination. Soft tissue disease progression: RECIST 1.1. Bone disease progression: PCWG2 criteria (≥2 or new lesions on bone scan compared with prior scan). Target lesion CR: disappearance of all target lesions, PR as ≥30% decrease in sum of longest diameter (LD) of target lesions, referencing baseline sum LD, SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing smallest sum LD since treatment start, PD ≥20% increase in sum of LD of target lesions, referencing smallest sum LD recorded since treatment start or appearance of ≥1 new lesions. Non-target lesions CR: disappearance of all non-target lesions and normalization of tumor marker level, SD: persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits, PD: appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: EoT; the median duration of treatment was 10.1 months.

  17. Change From Baseline to EoT in Bone Specific Alkaline Phosphatase

    Bone metabolism marker bone specific alkaline phosphatase levels were derived from blood samples collected.

    Time frame: Baseline and EoT; the median duration of treatment was 10.1 months.

  18. Change From Baseline in Urine N-Telopeptide

    Bone metabolism marker urine N-telopeptide levels were derived from urine samples collected.

    Time frame: Baseline and Week 9

Other outcomes

  1. Androgen Receptor Signaling Assessed by Expression and Localization of Androgen Receptor (AR), CYP17 Expression, Splice Variants, and Pathways Linked With Non-classical AR Signaling and Bone Development

    The endpoint was considered exploratory and no analysis was planned.

    Time frame: Baseline and Week 9

07

Results

Posted Feb 5, 2019

Participant flow

All participants in this all male study were enrolled at 1 site in the United States (US).

Participant flow — Overall Study
MilestoneEnzalutamide + Abiraterone + Prednisone
Started60
Treated60
Completed13
Not completed47
Withdrew: Progressive disease (pd)35
Withdrew: Withdrawal by subject2
Withdrew: Miscellaneous10

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

A treatment-emergent adverse event (TEAE) was defined as an adverse event occurring or worsening between the start of study treatment date and the latest date of 30 days after the last dose date or the 30-day follow-up visit date, and not later than the data cut-off date or the date of death. AEs, including abnormal clinical laboratory values, were graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) guidelines (V4.03).

Time frame:
From the first dose of study drug administration up 30 days following the last dose of study drug date, with a median duration of treatment of 10.1 months.
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsEnzalutamide + Abiraterone + Prednisone
Any TEAE60
Enzalutamide-related TEAEs56
Abiraterone-related TEAEs58
Prednisone-related TEAEs16
Deaths0
Serious TEAEs10
Enzalutamide-related serious TEAEs0
Abiraterone-related serious TEAEs2
Prednisone-related serious TEAEs0
TEAEs leading to discontinuation of enzalutamide3
Enza-related TEAEs leading to disc. of enza0
Abiraterone-related TEAEs leading to disc. of enza0
Prednisone-related TEAEs leading to disc. of enza0
TEAEs leading to discontinuation of abiraterone1
Abiraterone-related TEAEs leading to disc. of abi1
SecondaryChange From Baseline in Testosterone Concentration in Bone Marrow Aspirate

Testosterone concentration in bone marrow aspirate was measured by laboratory results derived from bone marrow samples processed through liquid chromatography mass spectrometry.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · pmol/L
Change From Baseline in Testosterone Concentration in Bone Marrow Aspirate
pmol/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Testosterone Concentration in Bone Marrow Aspirate-19.48 ± 257.923
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = 0.6150
SecondaryChange From Baseline in Dihydrotestosterone (DHT) Concentration in Bone Marrow Aspirate

DHT concentration in bone marrow aspirate was to be measured by laboratory results derived from bone marrow samples processed through liquid chromatography mass spectrometry. DHT bone data were not collected.

Time frame:
Baseline and Week 9

No measurements were reported for this outcome.

SecondaryChange From Baseline in Cortisol in Bone Marrow Aspirate

Cortisol in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · nmol/L
Change From Baseline in Cortisol in Bone Marrow Aspirate
nmol/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Cortisol in Bone Marrow Aspirate-46.86 ± 48.022
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = <.0001
SecondaryChange From Baseline in Androstenedione in Bone Marrow Aspirate

Androstenedione in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · nmol/L
Change From Baseline in Androstenedione in Bone Marrow Aspirate
nmol/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Androstenedione in Bone Marrow Aspirate-0.32 ± 0.342
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = <.0001
SecondaryChange From Baseline in Progesterone in Bone Marrow Aspirate

Progesterone in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · nmol/L
Change From Baseline in Progesterone in Bone Marrow Aspirate
nmol/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Progesterone in Bone Marrow Aspirate1.16 ± 1.104
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = <.0001
SecondaryChange From Baseline in Pregnenolone in Bone Marrow Aspirate

Pregnenolone in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · pg/ml
Change From Baseline in Pregnenolone in Bone Marrow Aspirate
pg/mlEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Pregnenolone in Bone Marrow Aspirate1381.44 ± 1513.324
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = <.0001
SecondaryChange From Baseline in Testosterone Concentration in Blood

Testosterone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · nmol/L
Change From Baseline in Testosterone Concentration in Blood
nmol/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Testosterone Concentration in Blood-0.06 ± 0.068
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = <.0001
SecondaryChange From Baseline in DHT Concentration in Blood

DHT concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry. The endpoint could not be analyzed since no participants had DHT levels over the lower limit of quantification (LLOQ).

Time frame:
Baseline and Week 9

No measurements were reported for this outcome.

SecondaryChange From Baseline in Cortisol Concentration in Blood

Cortisol concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · nmol/L
Change From Baseline in Cortisol Concentration in Blood
nmol/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Cortisol Concentration in Blood-48.81 ± 43.725
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = <.0001
SecondaryChange From Baseline in Androstenedione Concentration in Blood

Androstenedione concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · nmol/L
Change From Baseline in Androstenedione Concentration in Blood
nmol/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Androstenedione Concentration in Blood-0.24 ± 0.206
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = <.0001
SecondaryChange From Baseline in Progesterone Concentration in Blood

Progesterone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · nmol/L
Change From Baseline in Progesterone Concentration in Blood
nmol/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Progesterone Concentration in Blood1.43 ± 2.434
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = 0.0002
SecondaryChange From Baseline in Pregnenolone Concentration in Blood

Pregnenolone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · pg/ml
Change From Baseline in Pregnenolone Concentration in Blood
pg/mlEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Pregnenolone Concentration in Blood1507.42 ± 1699.335
Statistical analysis
  • Enzalutamide + Abiraterone + Prednisone · t-test, 2 sided · p = <.0001
SecondaryChange From Baseline to End-of-Treatment (EoT) in Prostate-Specific Antigen (PSA) Levels

Prostate-specific antigen progression by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) was defined as a PSA increase ≥25% and ≥2 ng/ml above the post-baseline nadir, and which was confirmed by the first subsequent value of 3 or more weeks later.

Time frame:
Baseline and EoT; the median duration of treatment was 10.1 months.
Reported as:
Geometric mean · ug/L
Change From Baseline to End-of-Treatment (EoT) in Prostate-Specific Antigen (PSA) Levels
ug/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline to End-of-Treatment (EoT) in Prostate-Specific Antigen (PSA) Levels36.35 ± 444.355
SecondaryProgression Free Survival (PFS)

PFS was measured as the time from the date of first dose of any drug of the study combination treatment until the first evidence of documented progression (a composite endpoint consisting of radiographic progression or PSA progression by PCWG2 or clinical deterioration) or death in the absence of progression (whichever came first) or the date last known to be progression free. The Kaplan-Meier (KM) 95% CI was based on Brookmeyer and Crowley robust non-parametric method.

Time frame:
Up to 1849 days
Reported as:
Median · days
Progression Free Survival (PFS)
daysEnzalutamide + Abiraterone + Prednisone
Progression Free Survival (PFS)251 (147.0 to 337.0)
SecondaryPercentage of Participants With Objective Response for Soft Tissue Lesions According to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)

Objective response was based on RECIST version 1.1 for soft tissue lesion on Magnetic resonance imaging (MRI) / Computerized tomography (CT) and the PCWG2 guidelines for bone lesions on bone scans and was defined as partial response (PR) or complete response (CR) based on the investigators' assessments of target, non-target and new lesions while on study treatment. The 95% for objective response rate was based on exact binomial 95% confidence interval (Clopper-Pearson).

Time frame:
Up to 1849 days
Reported as:
Median · percentage of participants
Percentage of Participants With Objective Response for Soft Tissue Lesions According to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)
percentage of participantsEnzalutamide + Abiraterone + Prednisone
Percentage of Participants With Objective Response for Soft Tissue Lesions According to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)68.8 (41.3 to 89.0)
SecondaryBone Scan Response at EoT

PD: ≥1 of 3 criteria: PSA progression: ≥2 rising PSA levels, interval of ≥1 week between each determination. Soft tissue disease progression: RECIST 1.1. Bone disease progression: PCWG2 criteria (≥2 or new lesions on bone scan compared with prior scan). Target lesion CR: disappearance of all target lesions, PR as ≥30% decrease in sum of longest diameter (LD) of target lesions, referencing baseline sum LD, SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing smallest sum LD since treatment start, PD ≥20% increase in sum of LD of target lesions, referencing smallest sum LD recorded since treatment start or appearance of ≥1 new lesions. Non-target lesions CR: disappearance of all non-target lesions and normalization of tumor marker level, SD: persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits, PD: appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
EoT; the median duration of treatment was 10.1 months.
Reported as:
Count of participants · Participants
Bone Scan Response at EoT
ParticipantsEnzalutamide + Abiraterone + Prednisone
Complete Response (CR)1
Progressive Disease (PD)15
Non-CR/Non-PD35
Not Evaluable1
SecondaryChange From Baseline to EoT in Bone Specific Alkaline Phosphatase

Bone metabolism marker bone specific alkaline phosphatase levels were derived from blood samples collected.

Time frame:
Baseline and EoT; the median duration of treatment was 10.1 months.
Reported as:
Geometric mean · ug/L
Change From Baseline to EoT in Bone Specific Alkaline Phosphatase
ug/LEnzalutamide + Abiraterone + Prednisone
Change From Baseline to EoT in Bone Specific Alkaline Phosphatase-5.18 ± 43.626
SecondaryChange From Baseline in Urine N-Telopeptide

Bone metabolism marker urine N-telopeptide levels were derived from urine samples collected.

Time frame:
Baseline and Week 9
Reported as:
Geometric mean · nmolBCE/mmolcreat
Change From Baseline in Urine N-Telopeptide
nmolBCE/mmolcreatEnzalutamide + Abiraterone + Prednisone
Change From Baseline in Urine N-Telopeptide29.35 ± 85.927
Other pre-specifiedAndrogen Receptor Signaling Assessed by Expression and Localization of Androgen Receptor (AR), CYP17 Expression, Splice Variants, and Pathways Linked With Non-classical AR Signaling and Bone Development

The endpoint was considered exploratory and no analysis was planned.

Time frame:
Baseline and Week 9

No measurements were reported for this outcome.

Adverse events

Collected over From the first dose of study drug administration up 30 days following the last dose of study drug date, with a median duration of treatment of 10.1 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Enzalutamide + Abiraterone + Prednisone0/60 (0%)9/60 (15%)60/60 (100%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventEnzalutamide + Abiraterone + Prednisone
Angina pectorisCardiac disorders1/60
Atrial fibrillationCardiac disorders1/60
Macular oedemaEye disorders1/60
Retinal vein occlusionEye disorders1/60
UrosepsisInfections and infestations1/60
Femur fractureInjury, poisoning and procedural complications1/60
Hip fractureInjury, poisoning and procedural complications1/60
Spinal compression fractureInjury, poisoning and procedural complications1/60
ArthralgiaMusculoskeletal and connective tissue disorders1/60
Spinal cord compressionNervous system disorders1/60
Most frequent other events
Showing 10 of 73
Most frequent other events
EventEnzalutamide + Abiraterone + Prednisone
FatigueGeneral disorders43/60
HyperglycaemiaMetabolism and nutrition disorders41/60
Blood alkaline phosphatase increasedInvestigations32/60
Hot flushVascular disorders27/60
Aspartate aminotransferase increasedInvestigations22/60
AnaemiaBlood and lymphatic system disorders21/60
Back painMusculoskeletal and connective tissue disorders20/60
ArthralgiaMusculoskeletal and connective tissue disorders19/60
HypertensionVascular disorders19/60
Alanine aminotransferase increasedInvestigations18/60

Baseline characteristics

The analysis population for all baseline measures consisted of all participants who were enrolled in the study.

Age, Continuous
Age, Continuous(Years)Enzalutamide + Abiraterone + Prednisone
Mean65.4 ± 9.37
Sex: Female, Male
Sex: Female, Male(Participants)Enzalutamide + Abiraterone + Prednisone
Female0
Male60
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Enzalutamide + Abiraterone + Prednisone
White51
Black or African American6
Asian2
Other1
Ethnicity
Ethnicity(Participants)Enzalutamide + Abiraterone + Prednisone
Not Hispanic or Latino57
Hispanic or Latino3
08

Study locations

1 site
  • Site US2492 MD Anderson Cancer Ctr
    Houston, Texas 77030, United States
09

References and documents

Publications

  • Assi R, Temraz S, Shamseddine A, Mukherji D. New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer. Curr Drug Targets. 2016;17(3):290-302. doi: 10.2174/1389450116666150907101044. PubMed 26343110 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2012 to primary completion in Jan 2018, 65 months.

Results were first posted in Feb 2019, 1 year 1 month after primary completion.

Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 65 months is above that.

Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2012
First posted
Jul 26, 2012
StartActual
Jul 9, 2012
Primary completionActual
Jan 4, 2018
CompletionActual
Jan 4, 2018
Results first posted
Feb 5, 2019
Last update
Dec 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01650194
Collaborators
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.
Responsible party
Sponsor
First posted
Jul 26, 2012
Start date
Jul 9, 2012
Primary completion
Jan 4, 2018
Completion
Jan 4, 2018
Results posted
Feb 5, 2019
Last update
Dec 10, 2024

Study contacts

Associate Medical Director
study director · Astellas Pharma Global Development

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion